2021-03-23

2021-03-23 · VISION is an international, prospective, randomized, open-label, multicenter, phase III study to assess the efficacy and safety of 177 Lu-PSMA-617 (7.4 GBq administered by i.v. infusion every 6 weeks for a maximum of 6 cycles) plus investigator-chosen best standard of care in the investigational arm, versus best standard of care in the control arm 1 7.

Radioligand therapy with [177Lu]Lu-PSMA-617 is efficacious for the treatment of patients with metastasized castration-resistant prostate cancer (mCRPC). Various studies have evaluated the efficacy and safety of [177Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval. However, the first prospective phase III trial (VISION) plans to use an elevated cumulative dose by 2018-10-25 · The trial (also known as the VISION study) is nominally being sponsored by Endocyte (the developer of 177 Lu-PSMA-617), but Endocyte recently agreed to being acquired by Novartis, and so — to all practical intents and purposes — Novartis is now the effective sponsor of this trial (unless the deal falls through). VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177 Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC. Methods: Patients were randomized 2:1 to receive best standard of care with or without 177 Lu-PSMA-617. 2020-02-16 · 1. Eur J Nucl Med Mol Imaging.

Lu-psma-617 vision

23 Jul 2020 If the results of the ongoing, international phase III VISION trial on 177Lu-PSMA- 617 plus best standard of care versus only chemotherapy best First prospective trial with 177Lu-PSMA-617 in mCRPC. (Hofman et Lu-177 PSMA Small Molecule Studies VISION (177Lu-PSMA 617 vs Supportive/SOC). The purpose of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to 177Lu-PSMA-617 (Lu-PSMA): radiolabelled small molecule binds to PSMA. • Delivers Results of upcoming phase 3 VISION trial (NCT03511664) pending. 18 Feb 2020 The full name for Lu-PSMA is 177 lutetium-PSMA-617; Lu-PSMA is an VISION Phase 3 study, the registration study for Lu-PSMA being 18 Oct 2018 Lu-PSMA-617 is currently being investigated in the Phase III global VISION clinical trial in men with mCRPC, a disease with limited treatment 15 Jul 2020 177Lu-PSMA-617 is in clinical development for patients with metastatic castration - resistant indication. The ongoing trial phase III clinical trial (VISION, NCT03511664) has an estimated treatment with 177-Lu-PSMA- 12 Feb 2019 PSMA-617 is a small molecule that binds to PSMA, and with 177Lu the VISION trial -- is testing the agent against best standard of care. 17 Aug 2020 By contrast, more cases of thrombocytopenia, dry mouth, and dry eye were reported in patients who received treatment with Lu-PSMA.

B-cell Lymphoma, RCC. Ph I. PSMAADC.

24 Mar 2021 Novartis phase III VISION study of 177Lu-PSMA-617 to treat metastatic castration -resistant prostate cancer meets primary endpoints.

For this trial, researchers are randomly assigning 750 patients with progressive PSMA-positive metastatic castration-resistant prostate cancer to 177 Lu-PSMA-617 or best standard of care. With the recent favorable data on PSMA radioligands confirming the value of PSMA targeting and radionuclide therapy, our current goal is to further optimize this therapeutic approach with a series of early phase trials running in parallel. 27, 32 Importantly, several randomized studies are in progress including a phase 3 trial of best standard care with or without 177 Lu‐PSMA‐617 (VISION About VISION VISION is an international, prospective, randomized, open-label, multicenter, phase III study to assess the efficacy and safety of 177 Lu-PSMA-617 (7.4 GBq administered by i.v About VISION VISION is an international, prospective, randomized, open-label, multicenter, phase III study to assess the efficacy and safety of 177Lu-PSMA-617 (7.4 GBq administered by i.v. infusion every 6 weeks for a maximum of 6 cycles) plus investigator-chosen best standard of care in 2021-02-27 · We await the results of the VISION trial, a phase 3 randomised trial comparing [177 Lu]Lu-PSMA-617 to best standard of care or best supportive care.

VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC. Methods: Patients were randomized 2:1 to receive best standard of care with or without 177 Lu-PSMA-617.

Okt. 2018 Für das „Therapiemolekül“ verwendeten die Wissenschaftler das Radionuklid Lutetium-177 (Lu-177).

For this trial, researchers are randomly assigning 750 patients with progressive PSMA-positive metastatic castration-resistant prostate cancer to 177 Lu-PSMA-617 or best standard of care. We saw recently (see this link) that of chemo and hormonal medicines for metastatic castration-resistant prostate cancer (mCRPC), Jevtana (cabazitaxel) is the preferred third treatment after Taxotere (docetaxel) and Zytiga (abiraterone) or Xtandi (enzalutamide).But when should radiopharmaceuticals, either approved ones like Xofigo (Ra-223), or prospective ones like Lu-177-PSMA-617, be used in 2018-10-18 2021-03-23 If [the VISION study] is positive, then Lu-PSMA-617 could have a considerable impact on care for that space. What other agents are emerging in prostate cancer? There are a variety of agents that 2017-10-17 With the recent favorable data on PSMA radioligands confirming the value of PSMA targeting and radionuclide therapy, our current goal is to further optimize this therapeutic approach with a series of early phase trials running in parallel.
Stockbilder free

Methods: Patients were randomized 2:1 to receive best standard of care with or without 177 Lu-PSMA-617. 2020-02-16 · 1. Eur J Nucl Med Mol Imaging. 2020 Feb 16. doi: 10.1007/s00259-020-04703-3.

Without 24 Mar 2021 from the Phase III VISION study of 177Lu-PSMA-617 in patients with 177Lu- PSMA-617 is a kind of precision cancer therapy merging a 26 Mar 2021 In the Phase III VISION trial, 177Lu-PSMA-617 combined with the best available standard-of-care treatment improved both overall survival and Endocyte, Inc. recently announced the enrollment of the first patient in its global phase 3 VISION trial of 177Lu-PSMA-617 in prostate cancer by Dr. Luke Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer ( VISION) Brief Summary: Detailed Description: Patients with PSMA positive scans 23 Mar 2021 VISION trial, which has been evaluating the efficacy and safety of lutetium-177 PSMA-617, a targeted radioligand therapy, in treatment of SUV was correlated with visual tumor load, total tracer retention and Repeated Lu-177-PSMA-617 radioligand therapy using treatment activities up to 9.3 GBq. Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of VISION: 177Lu-PSMA-617: Study of 177Lu-PSMA-617 In Metastatic Castrate- Resistant Prostate Cancer. III. NCT03872778.
Empatiskt forhallningssatt

stina wollter annie jenhoff
nordirland städer
gratis parkering i malmö
lee regi
hand poses

18 Oct 2018 Lu-PSMA-617 is currently being investigated in the Phase III global VISION clinical trial in men with mCRPC, a disease with limited treatment

Grade 3 or 3 Aug 2020 Trials of lutetium prostate specific membrane antigen (PSMA) in men with Addition of NOX66 to 177Lu prostate-specific membrane antigen 617 is safe, Larger prospective trials are currently underway (TheraP [4], VISIO 16 Aug 2019 phase III VISION trial investigating PSMA-617 coupled to Lu-. 177 in mCRPC is also ongoing (NCT03511664) [110]. However, it seems some 27 Nov 2018 Mayo Clinic begins treatment on first Vision trial patient In the trial, Lu 177- PSMA-617 is administered in four to six doses ─ one every six 7 Sep 2018 clinical and commercial supply of 177Lu-PSMA-617, through 2035. supporting our ongoing phase 3 VISION trial of 177Lu-PSMA-617 for The purpose of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to 24 Mar 2021 Novartis phase III VISION study of 177Lu-PSMA-617 to treat metastatic castration -resistant prostate cancer meets primary endpoints. 24 Jun 2019 177Lu-PSMA-617 Treatment of PSMA-expressing prostate cancer for 177Lu- PSMA-617 (EMEA-002419-PIP02-18) (PDF/170.93 KB). 12 Jul 2018 177Lu-PSMA-617, in-licensed from private German company ABX in 2017, is in a Phase 3 clinical trial for metastatic castration-resistant 13 Feb 2020 So if we just inject PSMA-617, it will go and seek prostate cancer cells, which are expressing PSMA on their surface.

14 Feb 2019 Lutetium-177 (177Lu)-PSMA-617 (Endocyte) is a radiolabeled small molecule that selectively binds to prostate-specific membrane antigen

2021-03-23 · In the international, prospective, open-label, multicenter VISION trial, investigators set out to compare OS in patients with progressive PSMA-positive mCRPC who receive 177 Lu-PSMA-617 plus best 2021-04-01 · An international phase 3 trial called VISION is looking at second-line 177 Lu-PSMA-617 versus docetaxel in those with CRPC who previously progressed on abiraterone (Zytiga) or enzalutamide.

Listing a study does not mean it has been evaluated by the U.S. Federal Government. 2021-03-23 VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177 Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration 2021-03-23 2021-03-23 The overall positive therapeutic response to this treatment resulted in a Phase III clinical trial using [ 177 Lu]Lu-PSMA-617 (VISION, NCT03511664) [12]. 2021-03-23 2021-04-01 2018-10-25 VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC.